Pulse Biosciences, Inc. Stock News

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 E...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference, in New York, New York. Management is scheduled to present on Thursday, N...

Pulse Biosciences, Inc. ( PLSE ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul LaViolette - President, CEO & Co-Chairman of the Board Jon Skinner - Chief Financial Officer Conference Call Participants Philip Taylor - Gilmartin Group LLC Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Ma...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the third quarter ended September 30, 2025. Recent Business Highlights Soft Tissue Ablation Initiated a multi-center clinic...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the enrollment of the first patient in its NANOCLAMP AF Study for the treatment of atrial fibrillation (AF). The successful first procedure was completed at St. Helen...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. Company management will host a cor...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 E...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical study results from the nPulse™ Cardiac Surgical System first-in-human feasibility study at the 39th European Association for Cardio-Thoracic Su...